Clinical trial NCT01079897: Efficacy and Safety of an Ectoine-containing Cream in the Treatment of Mild to Moderate Atopic Dermatitis
Official title: A Randomized, Comparator-controlled, Double-blind, Multicenter Intra-individual Clinical Trial to Evaluate the Efficacy and Safety of an Ectoine-containing Cream in the Treatment of Mild to Moderate Atopic Dermatitis
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Mild to Moderate Atopic Dermatitis
Keywords: Atopic dermatitis
Ectoine
Treatment
Atopiclair
Medical device
Lead sponsor: Bitop AG
Sponsor class: INDUSTRY
First posted: 2010-03-03
Enrollment: 64
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study evaluates the efficacy of the topical used ectoine-formulation EHK02-01 compared to Atopiclair. Patients are examined at visit 2 (baseline visit). The patient topically applies EHK02-01 or Zarzenda® twice daily on two symmetric lesional areas over 28 days. Response to therapy is recorded at each visit.


Eligibility criteria: Inclusion Criteria:

* Female or male individuals between 18 and 65 years in good general health diagnosed atopic dermatitis for ≥ 6 months, in active stage (active stage means severity as measured by overall IGA-Score between 1 and 4)
* At least two comparable areas of stable atopic eczema on bilateral symmetric corresponding sides of the extremities or the body (except for head and genital area), each of at least 10 cm², with a modified, objective local SCORAD of the test areas \> 5
* Both lesional areas of interest must have a difference in the modified, objective local SCORAD of ≤ 3
* Willingness to adhere to the schedule of the investigation, concomitant therapy prohibitions, restrictions, treatment regimen and procedures described in the CIP
* Written informed consent to participate in the trial, prior to any investigation related procedures, indicating an understanding of the purpose of the clinical investigation
* A patient of childbearing potential agrees to use a contraceptive methods for the duration of the investigation according to CPMP/ICH 286/95 note 3

Exclusion Criteria:

* Patients who are self-reported to be pregnant, nursing or planning pregnancy during the clinical investigation
* Patients with any skin disease that in the investigator's opinion may interfere with the conduct of the study or the evaluation of the results (e.g. psoriasis)
* Patients with a known malignancy
* Presence of any disease and/or condition and/or history of diseases and/or conditions that according to the investigator may interfere with the conduct of the investigation or the evaluation of the results (such as abnormal laboratory values, chronic inflammatory dis-eases, immunosuppressive diseases, autoimmune diseases, liver or kidney diseases, severe infectious diseases)
* Patients who did not respect the wash-out periods prior to and during the clinical investigation
* Vaccination within 6 days prior to enrolment and during the study.
* Patients with a known allergy against any ingredient of the test products
* Patients who are known to have had a substance abuse (drug or alcohol) problem within the previous 12 months
* Patients who participate in another clinical trial or have participated in another clinical trial within the last 30 days prior to the first day of investigation
* Patients who are involved in the organization of the clinical investigation
* Patients that are in any way dependant on the investigator

Primary outcomes:
measure: change of a modified, objective (local) SCORAD
timeFrame: 28 days
Secondary outcomes:
measure: Change of local IGA
timeFrame: 28 days
measure: Change of Pruritus
timeFrame: 28 days
measure: Patient's judgment on efficacy
timeFrame: 28 days
measure: AEs during treatment phase
timeFrame: 28 days
measure: Physical examination
timeFrame: 28 days
measure: Patient's assessment of tolerability and safe
timeFrame: 28 days
measure: change of the modified, objective local SCORAD
timeFrame: 7 days
Other outcomes:
Locations:
city: Berlin
country: Germany
facility: Hautarztzentrum Tegel
city: Freiburg
country: Germany
facility: Hautarztpraxis
city: Mahlow
country: Germany
facility: Gemeinschaftspraxis Mahlow
city: Potsdam
country: Germany
facility: Haut- und Lasercentrum Potsdam
Study officials:
affiliation: Professor Dr. med Wolfgang Vanscheid (Hautarzt, Allergologie, Phlebologie)
name: Wolfgang Vanscheidt, Professor
role: PRINCIPAL_INVESTIGATOR
affiliation: Haut- und Lasercentrum Potsdam
name: Tanja Fischer, Dr.
role: PRINCIPAL_INVESTIGATOR
affiliation: Hautarztzentrum Tegel
name: Martin Miehe, Dr.
role: PRINCIPAL_INVESTIGATOR
affiliation: Facharzt für Dermatologie
name: Michael Sebastian, Dr.
role: PRINCIPAL_INVESTIGATOR
References: